WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005012350) EPHA2 T-CELL EPITOPE AGONISTS AND USES THEREFOR
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/012350    International Application No.:    PCT/US2004/023931
Publication Date: 10.02.2005 International Filing Date: 22.07.2004
IPC:
A61K 38/17 (2006.01), C07K 14/47 (2006.01), C07K 14/705 (2006.01), G01N 33/50 (2006.01), G01N 33/569 (2006.01)
Applicants: UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION [US/US]; 200 Gardner Steel Conference Center, Thackeray & O'Hara Streets, Pittsburgh, PA 15260 (US) (For All Designated States Except US).
MEDIMMUNE, INC. [US/US]; One Medimmune Way, Gaithersburg, MD 20878 (US) (For All Designated States Except US).
STORKUS, Walter, J. [US/US]; (US) (For US Only).
KINCH, Michael, S. [US/US]; (US) (For US Only)
Inventors: STORKUS, Walter, J.; (US).
KINCH, Michael, S.; (US)
Agent: HIRSHMAN, Jesse, A.; Kirkpatrick & Lockhart LLP, Henry W. Oliver Building, 535 Smithfield Street, Pittsburgh, PA 15222-2312 (US)
Priority Data:
60/491,046 30.07.2003 US
Title (EN) EPHA2 T-CELL EPITOPE AGONISTS AND USES THEREFOR
(FR) AGONISTES D'EPITOPE DE CELLULE T EPHA2 T ET UTILISATIONS CORRESPONDANTES
Abstract: front page image
(EN)EphA2 T-cell epitope agonists are provided herein. The agonists include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-­cell epitope agonists are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The agonists also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 agonists also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.
(FR)La présente invention concerne des agonistes d'épitope de cellule T EphA2. Les agonistes comprennent des peptides correspondant à des fragments spécifiques de protéine EphA2 humaine contenant un ou plusieurs épitopes de cellule T et des dérivés classiques correspondants. Les agonistes d'épitope de cellule T EphA2 sont utiles dans un dosage, tel que le dosage ELISPOT, qui peut être utilisé pour déterminer et/ou quantifier la faculté de réponse immunitaire à EphA2. Les agonistes sont également utiles dans des méthodes de modulation de la réactivité du système immunitaire du patient à EphA2, ce qui présente une utilité substantielle en tant que traitement pour les cancers avec surexpression de EphA2, tels que l'hypernéphrome. Les agonistes EphA2 peuvent également être utilisés pour vacciner un patient contre EphA2, au moyen de méthodes in vivo ou ex vivo.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)